Cellworks Omics Biology Model (CBM) to predict therapy response and identify biomarkers for all-trans retinoic acid (ATRA) benefit as addition to induction chemotherapy in adults with acute myeloid leukemia (AML).

Scott C. Howard,Ansu Kumar,Himanshu Grover,Vivek Patil,Ashish Kumar Agrawal,Anuj Tyagi,S. Mohapatra,Humera Azam,Karthik Sundara Raju,Mohammed Sauban,Rahul K Raman,Neelesh Lunkad,Upasana Mitra,Poornachandra G,Nirjhar Mundkur,Neha Gupta,Jyoti Chauhan,Swati Khandelwal,Shweta Kapoor,Michael Castro

Cellworks Omics Biology Model (CBM) to predict therapy response and identify biomarkers for all-trans retinoic acid (ATRA) benefit as addition to induction chemotherapy in adults with acute myeloid leukemia (AML).

2021

7027Background: ATRA combined with arsenic trioxide revolutionized the treatment of APL. Based on promising in vitro data, several clinical trials evaluated ATRA combinations in non-APL AML, in whi...

Keywords:

Medicine
therapy response
all trans
Omics
Cancer research
Myeloid leukemia
Clinical trial
Retinoic acid
Arsenic trioxide
Induction chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations